Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRPR | P30550 | 3/20 | 0.39 |
| ▸ | F2 | P00734 | 4/20 | 0.38 |
| ▸ | GLP1R | P43220 | 5/20 | 0.38 |
| ▸ | SCTR | P47872 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.37 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30513616 | 0.92 | MME (0.38) | GRPRSLC15A2 | |
| SCHEMBL29630577 | 0.92 | MME (0.38) | GRPRSLC15A2 | |
| SCHEMBL29715881 | 0.91 | MME (0.38) | SLC15A2 | |
| SCHEMBL29590512 | 0.91 | MME (0.38) | SLC15A2 | |
| SCHEMBL31453797 | 0.91 | MME (0.38) | SLC15A2 | |
| SCHEMBL31108160 | 0.91 | MME (0.38) | SLC15A2 | |
| SCHEMBL29590556 | 0.90 | OPRD1 (0.39) | F2OPRD1OPRM1OPRK1 | |
| SCHEMBL29630620 | 0.89 | OPRD1 (0.38) | F2OPRD1OPRM1OPRK1 | |
| SCHEMBL31482979 | 0.88 | MME (0.38) | SLC15A2 | |
| SCHEMBL29630607 | 0.88 | MME (0.38) | SLC15A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | GRPR 3134/4885F2 899/4885GLP1R 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.